What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 686-691

  Assassi, Shervin ^a   Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gene expression profiling; Pathogenesis; Systemic sclerosis

Indexed keywords

ADIPONECTIN; BETA CATENIN; BIOLOGICAL MARKER; BLOCKING ANTIBODY; CARBON MONOXIDE; CENTROMERE ANTIBODY; CHEMOATTRACTANT; CXCL11 CHEMOKINE; FRIZZLED PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENOMIC DNA; HLA DRB5 ANTIGEN; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; LYMPHOID ENHANCER FACTOR 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RITUXIMAB; SOMATOMEDIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ANTIGEN PRESENTATION; ATOPIC DERMATITIS; BRONCHIECTASIS; CLINICAL FEATURE; DEMOGRAPHY; DERMATOMYOSITIS; DISEASE DURATION; DISEASE SEVERITY; ENDOCYTOSIS; FIBROBLAST; FIBROGENESIS; FOLLOW UP; FORCED VITAL CAPACITY; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HUMAN; LIPID METABOLISM; LIPOGENESIS; LUNG DISEASE; LUNG FIBROSIS; LUPUS VULGARIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROADIPOCYTE; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TISSUE INJURY;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA-DRB5 CHAINS; HUMANS; INTERFERONS; INTERLEUKIN-13; MICE; SCLERODERMA, SYSTEMIC; SKIN; WNT SIGNALING PATHWAY;

EID: 84885327368     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434672.77891.41     Document Type: Review

References (35)

1. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54:1961-1973
2. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: E2696
3. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003; 100:12319-12324
4. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63:783-794
5. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arthritis Rheum 2010; 62:589-598
6. Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45: 694-702
7. York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007; 56:1010-1020
8. Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-Associated pulmonary arterial hypertension. Arthritis Rheum 2011; 63:1718-1728
9. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130:694-705
10. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58:1465-1474
11. Grigoryev DN, Mathai SC, Fisher MR, et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008; 151:197-207
12. .Wei J, Fang F, Lam AP, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012; 64:2734-2745
13. Hong KM, Belperio JA, Keane MP, et al. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-Activated receptor gamma. J Biol Chem 2007; 282:22910-22920
14. .Lakota K, Wei J, Carns M, et al. Levels of adiponectin, a marker for PPARgamma activity, correlate with skin fibrosis in systemic sclerosis: Potential utility as biomarker? Arthritis Res Ther 2012; 14:R102
15. Kusminski CM, Scherer PE. The road from discovery to clinic: Adiponectin as a biomarker of metabolic status. Clin Pharmacol Ther 2009; 86:592-595
16. Ghosh AK, Bhattacharyya S, Lakos G, et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-Activated receptor gamma. Arthritis Rheum 2004; 50:1305-1318
17. Wu M, Melichian DS, Chang E, et al. Rosiglitazone abrogates bleomycininduced scleroderma and blocks profibrotic responses through peroxisome proliferator-Activated receptor-gamma. Am J Pathol 2009; 174:519-533
18. Shi-Wen X, Eastwood M, Stratton RJ, et al. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford) 2010; 49:259-263
19. Wei J, Ghosh AK, Sargent JL, et al. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis. PLoS One 2010; 5:e13778
20. .Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012; 180:1080-1094
21. Fulkerson PC, Fischetti CA, Hassman LM, et al. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol 2006; 35:337-346
22. Hasegawa M, Fujimoto M, Matsushita T, et al. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011; 30:231-237
23. .Pendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012; 132:1363-1373
24. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60:578-583
25. Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: Specificity and heterogeneity across diseases. PLoS One 2012; 7:e29161
26. Krathen MS, Fiorentino D, Werth VP. Dermatomyositis. Curr Dir Autoimmun 2008; 10:313-332
27. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95:15623-15628
28. Sanda C, Weitzel P, Tsukahara T, et al. Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 2006; 26:462-472
29. Indraccolo S, Pfeffer U, Minuzzo S, et al. Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 2007; 178:1122-1135
30. Saaf AM, Tengvall-Linder M, Chang HY, et al. Global expression profiling in atopic eczema reveals reciprocal expression of inflammatory and lipid genes. PLoS One 2008; 3:e4017
31. Gudjonsson JE, Ding J, Li X, et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009; 129:2795-2804
32. .Liu X, Mayes MD, Tan FK, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 2013; 65:226-235
33. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferonregulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3:e491
34. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum 2009; 60:3098-3107
35. Odani T, Yasuda S, Ota Y, et al. Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease. Rheumatology (Oxford) 2012; 51:1765-1774